Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions

Research output: Contribution to journalReview articlepeer-review

44 Scopus citations


Although prescribing information (PI) is often the initial source of information when identifying potential drug-drug interactions, it may only provide a limited number of exemplars or only reference a class of medications without providing any specific medication examples. In the case of medical cannabis and medicinal cannabinoids, this is further complicated by the fact that the increased therapeutic use of marijuana extracts and cannabidiol oil will not have regulatory agency approved PI. The objective of this study was to provide a detailed and comprehensive drug-drug interaction list that is aligned with cannabinoid manufacturer PI. The cannabinoid drug-drug interaction information is listed in this article and online supplementary material as a PRECIPITANT (cannabinoid) medication that either INHIBITS/INDUCES the metabolism or competes for the same SUBSTRATE target (metabolic enzyme) of an OBJECT (OTHER) medication. In addition to a comprehensive list of drug-drug interactions, we also provide a list of 57 prescription medications displaying a narrow therapeutic index that are potentially impacted by concomitant cannabinoid use (whether through prescription use of cannabinoid medications or therapeutic/recreational use of cannabis and its extracts).

Original languageEnglish (US)
Pages (from-to)61-73
Number of pages13
JournalMedical Cannabis and Cannabinoids
Issue number1
StatePublished - Aug 1 2020

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Complementary and alternative medicine
  • Pharmacology (medical)


Dive into the research topics of 'Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions'. Together they form a unique fingerprint.

Cite this